Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention 09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 28, 811-822, May 1, 1968]
© 1968 American Association for Cancer Research
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Management of Patients with Malignant Lymphoma: A Comparative Study with Cyclophosphamide and Vinca Alkaloids6

A large cooperative study to obtain quantitative information about the use of cyclophosphamide and the vinca alkaloids as therapeutic agents in patients with malignant lymphoma was done. For remission, induction phase patients with Hodgkin's disease were randomly allocated to cyclophosphamide and vinblastine. Patients with lymphosarcoma or reticulum cell sarcoma were given cyclophosphamide or vincristine. In patients with Hodgkin's disease without prior chemotherapy, vinblastine administration induced a higher proportion of remissions than cyclophosphamide. In all other disease categories, cyclophosphamide-treated groups had a consistently higher remission induction rate when compared to vinca-treated patients. The average duration of remission maintained with a placebo, oral cyclophosphamide, or intermittent intravenous cyclophosphamide was also determined for each disease category. In all categories of patients, the average duration of an unmaintained remission (placebo administration) was 4 to 6 weeks irrespective of the drug inducing the remission. The duration of remissions maintained with daily oral cyclophosphamide administration was longer when compared to placebo administration. The total time from remission induction to fastness to oral cyclophosphamide or intermittent parenteral cyclophosphamide was similar. The duration of the remissions was always longer for complete as compared to partial remissions. The survival of patients from the start of study was comparable for either vinca- or cyclophosphamide-treated groups.

6 Presented in part at the American Association for Cancer Research, May, 1966, Denver, Colorado.

Received 9/ 8/67. Accepted 1/12/68.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1968 by the American Association for Cancer Research.